When

Friday, May 01, 2026

11:00 AM-12:00 PM ET

WheRE

Dublin, GA

Laurens County Health Department
Conference Room
654 County Farm Road
Dublin, GA 31021

 

faculty
Gregory Felzien, MD, AAHIVS
Diplomat: Internal Medicine and Infectious Disease
Medical Director
Positive Impact Health Centers
Atlanta, Georgia

Lunch will be provided.

Target Audience

The educational design of this activity addresses the needs of community-based clinicians providing HIV prevention care, including primary care, OB/GYN, pharmacy, addiction medicine, and urgent care professionals (physicians, NPs, PAs, nurses, and pharmacists).

Program Overview

ACTIVATE PrEP is a CME/CE meeting series designed to help clinics who are already prescribing preexposure prophylaxis (PrEP) to optimize same-day and rapid initiation workflows. Many community health centers and sexual health clinics have the intent and infrastructure to offer immediate PrEP initiation but face persistent challenges that impede consistent implementation, including workflow inefficiencies, limited staff capacity, pharmacy coordination, and reimbursement uncertainty.

Expert faculty will engage interprofessional care teams through a one-hour customized in-clinic learning session, assessing site-specific barriers, reviewing best practices, and developing actionable plans to improve timeliness and equity in PrEP delivery. Structured follow-up consultations will support progress toward defined implementation goals, ensuring measurable and sustainable workflow change. Educational resources and community outreach tools/support will further extend impact.

Educational Objectives

After completing this activity, the participant should be better able to:

  1. Implement guideline-aligned same-day/rapid PrEP initiation workflows, including eligibility, testing, and prescribing
  2. Diagnose and optimize site-specific barriers (order sets, standing orders, staffing, and access pathways)
  3. Integrate patient-centered counseling strategies that reduce stigma and support uptake/adherence
  4. Define clinic pathways to offer long-acting PrEP when clinically appropriate and operationally feasible
  5. Develop and track a site-specific action plan with roles, milestones, and sustainability considerations

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour, including <Rx> pharmacotherapeutic contact hours, is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pretest, posttest, and evaluation form.

Integritas Contact Information

For information about the accreditation (ACCME credit) of this program, please contact Integritas at info@exchangecme.com.

Global Contact Information

For information about the accreditation (ANCC credit) of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Fee Information& Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Relevant Financial Relationships

Integritas Communications and Global adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Gregory “Grey” Felzien, MD, AAHIVS: Nothing to disclose

The planners and managers at Integritas Communications and Global Education Group have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Register Now

attend event
Related events
MAY
17
2026
A CALIBRATE™ Program
1.50 CME

Gaining Control of Eosinophilic Disorders

Best Practices for Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis

Time: 6:30 PM-8:30 PM ET
Venue: Rosen Center
Location: Orlando, FL
Faculty: Praveen Akuthota, MD; Philip Seo, MD, MHS; Michael E. Wechsler, MD, MMSc
MAY
17
2026
A CALIBRATE™ Program
1.50 CME

Gaining Control of Eosinophilic Disorders

Best Practices for Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis

Time: 7:00 PM-8:30 PM ET
Venue: Live Stream
Location: Live Stream
Faculty: Praveen Akuthota, MD; Philip Seo, MD, MHS; Michael E. Wechsler, MD, MMSc
MAY
18
2026
Science in the Spotlight™
1.50 CME

IL-33 in the Spotlight:

Exploring New Pathways for COPD and Acute Respiratory Infections

Time: 6:30 PM-8:30 PM ET
Venue: Hilton Orlando
Location: Orlando, FL
Faculty: Jonathan M. Hand, MD, FIDSA, FAST; Professor Dave Singh MD, FERS, FBPhS; Professor Tom Wilkinson, MA Cantab, MBBS, PhD, FRCP, FERS
MAY
18
2026
Science in the Spotlight™
1.50 CME

IL-33 in the Spotlight:

Exploring New Pathways for COPD and Acute Respiratory Infections